Option chain shows key data for Lexaria Bioscience's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lexaria Bioscience.

Lexaria Bioscience (NASDAQ:LEXX) Stock, Option Chain

LEXARIA BIOSCIENCE CORP

Lexaria Bioscience

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Movers

News

Pre-Market Outlook

Markets

Trading Ideas

ALBT

ANNX

BARK

CAPT

Core Scientific, Inc. - Class A Common Stock

CORZ

FGEN

LEXX

MBOT

MLGO

NIVF

PLTN

SQNS

WIMI

YGMZ

Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

Intraday Update

ACAD

AEVA

ASAN

ASRT

BCAN

BLDE

The Beachbody Company, Inc. Class A Common Stock

BODI

BWMN

CLRO

CRBU

CTMX

DTSS

ENPH

ESGL

FNCH

GERN

GOEV

HRTG

IONM

JANX

JFBR

KITT

LGCL

LICY

MNSO

NRXP

NUKK

OCUL

ONON

ORCL

PACK

PRST

RERE

RGLS

RNLX

SGLY

SMXT

SPPL

TALK

VINC

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.

Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Lexaria Bioscience shares are trading lower by 6.5% Thursday morning. The company finalized agreements for a registered direct offering.

Why Lexaria Bioscience (LEXX) Shares Are Moving

Lexaria Bioscience Corp

Press Releases

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Lexaria Releases Annual Letter from the CEO

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

LEXXW

AN2 Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

CalciMedica

Cara Therapeutics

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Grace Therapeutics

Impact BioMedical

IGC Pharma

Opus Genetics

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lipocine

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

NRX Pharmaceuticals

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Scilex Holding

SCYNEXIS

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

VYNE Therapeutics

HC Wainwright & Co.

Maxim Group

Comments

Lexaria Bioscience

Lexaria Bioscience (LEXX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga